In conclusion, as depicted in our schematic abstract (Figure 8), our results highlight the therapeutic efficacy of LCC-09 as a regulator and/or disruptor of multiple oncogenic signaling and crucial drivers of GBM progression or TMZ resistance, such as DRD4, CDK6, and AKT, through the upregulation or re-expression of master tumor suppressor, miR-34a. Here, DRD4 is linked to glioblastoma.